Childhood GPA, EGPA, and MPA

Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a term used to describe rare primary systemic vasculitides affecting small and medium-sized blood vessels. AAV diseases which include Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA),...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.) Fla.), 2020-02, Vol.211, p.108325-108325, Article 108325
Hauptverfasser: Jariwala, Mehul, Laxer, Ronald M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 108325
container_issue
container_start_page 108325
container_title Clinical immunology (Orlando, Fla.)
container_volume 211
creator Jariwala, Mehul
Laxer, Ronald M.
description Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a term used to describe rare primary systemic vasculitides affecting small and medium-sized blood vessels. AAV diseases which include Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), Microscopic Polyangiitis (MPA) and renal limited ANCA vasculitis. These multisystemic disorders involve upper and lower respiratory tract and kidneys associated with organ damage and long term sequelae. Newer understanding of pathogenesis in AAV have paved the way for clinical research with different biologic therapies. In spite of the paucity of clinical trials in pediatric AAV, the long-term survival of patients with AAV has improved dramatically. International collaborations will help to conduct clinical trials in pediatric AAV and help in better understanding of remission rates, relapse rates, and other outcomes. This article aims to provide a comprehensive review of pediatric AAV with a focus on epidemiology, disease pathogenesis, treatment trials, and prognosis.
doi_str_mv 10.1016/j.clim.2019.108325
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2327383505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521661619305376</els_id><sourcerecordid>2327383505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-728e27c54249bd655d7395046cb6d00a3b1415ff8fa12be916e07ed3a1291d2c3</originalsourceid><addsrcrecordid>eNp9kF9LwzAUxYMobk6_gIjs0Qdbc5MmacGXMeYUJu5Bn0Ob3LKMdp3JNvDb29rpoy_3H-ccuD9CroHGQEE-rGNTuTpmFLL2kHImTsgQBINIUS5Oj7OUIAfkIoQ1pVQwJs_JgEPKVZKIIbmZrlxlV01jx_Pl5H48-6n5xo5fl5NLclbmVcCrYx-Rj6fZ-_Q5WrzNX6aTRWS4kLtIsRSZMiJhSVZYKYRVPBM0kaaQltKcF5CAKMu0zIEVmIFEqtDydsvAMsNH5K7P3frmc49hp2sXDFZVvsFmHzTjTPGUCypaKeulxjcheCz11rs6918aqO6o6LXuqOiOiu6ptKbbY_6-qNH-WX4xtILHXoDtlweHXgfjcGPQOo9mp23j_sv_BptVbik</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2327383505</pqid></control><display><type>article</type><title>Childhood GPA, EGPA, and MPA</title><source>Elsevier ScienceDirect Journals</source><creator>Jariwala, Mehul ; Laxer, Ronald M.</creator><creatorcontrib>Jariwala, Mehul ; Laxer, Ronald M.</creatorcontrib><description>Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a term used to describe rare primary systemic vasculitides affecting small and medium-sized blood vessels. AAV diseases which include Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), Microscopic Polyangiitis (MPA) and renal limited ANCA vasculitis. These multisystemic disorders involve upper and lower respiratory tract and kidneys associated with organ damage and long term sequelae. Newer understanding of pathogenesis in AAV have paved the way for clinical research with different biologic therapies. In spite of the paucity of clinical trials in pediatric AAV, the long-term survival of patients with AAV has improved dramatically. International collaborations will help to conduct clinical trials in pediatric AAV and help in better understanding of remission rates, relapse rates, and other outcomes. This article aims to provide a comprehensive review of pediatric AAV with a focus on epidemiology, disease pathogenesis, treatment trials, and prognosis.</description><identifier>ISSN: 1521-6616</identifier><identifier>EISSN: 1521-7035</identifier><identifier>DOI: 10.1016/j.clim.2019.108325</identifier><identifier>PMID: 31837445</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>ANCA ; ANCA associated vasculitis ; Childhood vasculitis</subject><ispartof>Clinical immunology (Orlando, Fla.), 2020-02, Vol.211, p.108325-108325, Article 108325</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-728e27c54249bd655d7395046cb6d00a3b1415ff8fa12be916e07ed3a1291d2c3</citedby><cites>FETCH-LOGICAL-c356t-728e27c54249bd655d7395046cb6d00a3b1415ff8fa12be916e07ed3a1291d2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clim.2019.108325$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31837445$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jariwala, Mehul</creatorcontrib><creatorcontrib>Laxer, Ronald M.</creatorcontrib><title>Childhood GPA, EGPA, and MPA</title><title>Clinical immunology (Orlando, Fla.)</title><addtitle>Clin Immunol</addtitle><description>Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a term used to describe rare primary systemic vasculitides affecting small and medium-sized blood vessels. AAV diseases which include Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), Microscopic Polyangiitis (MPA) and renal limited ANCA vasculitis. These multisystemic disorders involve upper and lower respiratory tract and kidneys associated with organ damage and long term sequelae. Newer understanding of pathogenesis in AAV have paved the way for clinical research with different biologic therapies. In spite of the paucity of clinical trials in pediatric AAV, the long-term survival of patients with AAV has improved dramatically. International collaborations will help to conduct clinical trials in pediatric AAV and help in better understanding of remission rates, relapse rates, and other outcomes. This article aims to provide a comprehensive review of pediatric AAV with a focus on epidemiology, disease pathogenesis, treatment trials, and prognosis.</description><subject>ANCA</subject><subject>ANCA associated vasculitis</subject><subject>Childhood vasculitis</subject><issn>1521-6616</issn><issn>1521-7035</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kF9LwzAUxYMobk6_gIjs0Qdbc5MmacGXMeYUJu5Bn0Ob3LKMdp3JNvDb29rpoy_3H-ccuD9CroHGQEE-rGNTuTpmFLL2kHImTsgQBINIUS5Oj7OUIAfkIoQ1pVQwJs_JgEPKVZKIIbmZrlxlV01jx_Pl5H48-6n5xo5fl5NLclbmVcCrYx-Rj6fZ-_Q5WrzNX6aTRWS4kLtIsRSZMiJhSVZYKYRVPBM0kaaQltKcF5CAKMu0zIEVmIFEqtDydsvAMsNH5K7P3frmc49hp2sXDFZVvsFmHzTjTPGUCypaKeulxjcheCz11rs6918aqO6o6LXuqOiOiu6ptKbbY_6-qNH-WX4xtILHXoDtlweHXgfjcGPQOo9mp23j_sv_BptVbik</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Jariwala, Mehul</creator><creator>Laxer, Ronald M.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202002</creationdate><title>Childhood GPA, EGPA, and MPA</title><author>Jariwala, Mehul ; Laxer, Ronald M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-728e27c54249bd655d7395046cb6d00a3b1415ff8fa12be916e07ed3a1291d2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>ANCA</topic><topic>ANCA associated vasculitis</topic><topic>Childhood vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jariwala, Mehul</creatorcontrib><creatorcontrib>Laxer, Ronald M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical immunology (Orlando, Fla.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jariwala, Mehul</au><au>Laxer, Ronald M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Childhood GPA, EGPA, and MPA</atitle><jtitle>Clinical immunology (Orlando, Fla.)</jtitle><addtitle>Clin Immunol</addtitle><date>2020-02</date><risdate>2020</risdate><volume>211</volume><spage>108325</spage><epage>108325</epage><pages>108325-108325</pages><artnum>108325</artnum><issn>1521-6616</issn><eissn>1521-7035</eissn><abstract>Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a term used to describe rare primary systemic vasculitides affecting small and medium-sized blood vessels. AAV diseases which include Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), Microscopic Polyangiitis (MPA) and renal limited ANCA vasculitis. These multisystemic disorders involve upper and lower respiratory tract and kidneys associated with organ damage and long term sequelae. Newer understanding of pathogenesis in AAV have paved the way for clinical research with different biologic therapies. In spite of the paucity of clinical trials in pediatric AAV, the long-term survival of patients with AAV has improved dramatically. International collaborations will help to conduct clinical trials in pediatric AAV and help in better understanding of remission rates, relapse rates, and other outcomes. This article aims to provide a comprehensive review of pediatric AAV with a focus on epidemiology, disease pathogenesis, treatment trials, and prognosis.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31837445</pmid><doi>10.1016/j.clim.2019.108325</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1521-6616
ispartof Clinical immunology (Orlando, Fla.), 2020-02, Vol.211, p.108325-108325, Article 108325
issn 1521-6616
1521-7035
language eng
recordid cdi_proquest_miscellaneous_2327383505
source Elsevier ScienceDirect Journals
subjects ANCA
ANCA associated vasculitis
Childhood vasculitis
title Childhood GPA, EGPA, and MPA
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T14%3A43%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Childhood%20GPA,%20EGPA,%20and%20MPA&rft.jtitle=Clinical%20immunology%20(Orlando,%20Fla.)&rft.au=Jariwala,%20Mehul&rft.date=2020-02&rft.volume=211&rft.spage=108325&rft.epage=108325&rft.pages=108325-108325&rft.artnum=108325&rft.issn=1521-6616&rft.eissn=1521-7035&rft_id=info:doi/10.1016/j.clim.2019.108325&rft_dat=%3Cproquest_cross%3E2327383505%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2327383505&rft_id=info:pmid/31837445&rft_els_id=S1521661619305376&rfr_iscdi=true